Q-omics provides the consensus-scored FOSB profile across patient tissues and cancer cell-line models. FOSB expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FOSB is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, FOSB protein abundance shows 14,992 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, BLCA, and HNSC as cancer lineages where FOSB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOSB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOSB survival associations across molecular data types. FOSB RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOSB RNA expression–survival associations across cancer types. High FOSB expression shows unfavorable associations in ACC, SCLC and OV, but favorable associations in KICH, LIHC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FOSB RNA expression.
This table summarizes FOSB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FOSB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOSB shows lower tumor expression in BLCA, KICH, KIRP, HNSC, THCA and LIHC. The BLCA box plot shows higher FOSB RNA expression in normal versus tumor tissue (log2 FC = −3.780, t-test p < 0.001).
This table shows molecular features associated with FOSB in patient tissues and cancer cell lines. In patient samples, FOSB shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, FOSB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
